Linda Henry

37.8k total citations · 20 hit papers
279 papers, 25.0k citations indexed

About

Linda Henry is a scholar working on Epidemiology, Hepatology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Linda Henry has authored 279 papers receiving a total of 25.0k indexed citations (citations by other indexed papers that have themselves been cited), including 195 papers in Epidemiology, 153 papers in Hepatology and 46 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Linda Henry's work include Liver Disease Diagnosis and Treatment (183 papers), Hepatitis C virus research (87 papers) and Liver Disease and Transplantation (84 papers). Linda Henry is often cited by papers focused on Liver Disease Diagnosis and Treatment (183 papers), Hepatitis C virus research (87 papers) and Liver Disease and Transplantation (84 papers). Linda Henry collaborates with scholars based in United States, China and United Kingdom. Linda Henry's co-authors include Zobair M. Younossi, Aaron B. Koenig, Yousef Fazel, Dinan Abdelatif, Quentin M. Anstee, Maria Stepanova, Mohammed Eslam, Timothy Hardy, Elisabetta Bugianesi and M. Marietti and has published in prestigious journals such as SHILAP Revista de lepidopterología, Gastroenterology and Journal of the American College of Cardiology.

In The Last Decade

Linda Henry

274 papers receiving 24.6k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes

2015 7.7k citations Zobair M. Younossi, Linda Henry et al. Hepatology profile →
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention

2017 3.9k citations Zobair M. Younossi, Linda Henry et al. profile →
The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review

2023 1.5k citations Zobair M. Younossi, James M. Paik et al. Hepatology profile →
The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe

2016 916 citations Zobair M. Younossi, Linda Henry et al. Hepatology profile →
Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009

2015 593 citations Zobair M. Younossi, Linda Henry et al. Hepatology profile →
Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis

2020 586 citations Yee Hui Yeo, Leslie Y. Kam et al. profile →
Epidemiology of COVID‐19: A systematic review and meta‐analysis of clinical characteristics, risk factors, and outcomes

2020 434 citations Linda Henry, Ramsey Cheung et al. profile →
Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in the United States and the Rest of the World

2015 411 citations Linda Henry, Zobair M. Younossi et al. Clinics in Liver Disease profile →
Epidemiology of chronic liver diseases in the USA in the past three decades

2019 387 citations Zobair M. Younossi, Maria Stepanova et al. profile →
Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States

2020 373 citations Zobair M. Younossi, Maria Stepanova et al. Clinical Gastroenterology and Hepatology profile →
The Global Burden of Liver Disease

2023 221 citations Zobair M. Younossi, Linda Henry et al. Clinical Gastroenterology and Hepatology profile →
Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

2022 172 citations Yee Hui Yeo, Linda Henry et al. profile →
Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 persons

2023 159 citations Linda Henry, Ramsey Cheung et al. Journal of Hepatology profile →
Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease

2024 156 citations Zobair M. Younossi, James M. Paik et al. Journal of Hepatology profile →
Global burden of NAFLD and chronic liver disease among adolescents and young adults

2021 153 citations James M. Paik, Khaled W. Kabbara et al. Hepatology profile →
Lifestyle interventions in nonalcoholic fatty liver disease

2023 145 citations Zobair M. Younossi, Shira Zelber‐Sagi et al. profile →
Review article: the epidemiologic burden of non‐alcoholic fatty liver disease across the world

2022 123 citations Linda Henry, James M. Paik et al. Alimentary Pharmacology & Therapeutics profile →
Are there outcome differences between NAFLD and metabolic‐associated fatty liver disease?

2022 120 citations Zobair M. Younossi, James M. Paik et al. Hepatology profile →
The burden of nonalcoholic fatty liver disease (NAFLD) is rapidly growing in every region of the world from 1990 to 2019

2023 96 citations James M. Paik, Linda Henry et al. Hepatology Communications profile →
The changing epidemiology of adult liver transplantation in the United States in 2013-2022: The dominance of metabolic dysfunction–associated steatotic liver disease and alcohol-associated liver disease

2023 71 citations Zobair M. Younossi, Maria Stepanova et al. Hepatology Communications profile →

Peers

Countries citing papers authored by Linda Henry

Since Specialization

Citations

This map shows the geographic impact of Linda Henry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Linda Henry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Linda Henry more than expected).

Fields of papers citing papers by Linda Henry

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Linda Henry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Linda Henry. The network helps show where Linda Henry may publish in the future.

Co-authorship network of co-authors of Linda Henry

This figure shows the co-authorship network connecting the top 25 collaborators of Linda Henry. A scholar is included among the top collaborators of Linda Henry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Linda Henry. Linda Henry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Managing MASLD Through Preventive Hepatology: Integrating Policy Reform, Public Health and Personalised Care 2025 ·Liver International ·Zobair M. Younossi, Vincent Wai‐Sun Wong, Emmanuel Tsochatzis, Laurent Castéra, (unknown), Linda Henry, Shira Zelber‐Sagi	1
2	Health-related quality of life (HRQL) assessments in a 52-week, double-blind, randomized, placebo-controlled phase III study of resmetirom (MGL-3196) in patients with metabolic dysfunction–associated steatohepatitis (MASH) and fibrosis 2024 ·Hepatology ·Zobair M. Younossi, (unknown), Andrei Racila, Linda Henry, Dominic Labriola, Rebecca Taub, Fatema Nader	17
3	Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease breakdown → 2024 ·Journal of Hepatology ·Zobair M. Younossi, James M. Paik, Maria Stepanova, Janus P. Ong, Saleh A. Alqahtani, Linda Henry	156
4	Noninvasive Tests Used in Risk Stratification of Patients with Nonalcoholic Fatty Liver Disease 2023 ·Clinics in Liver Disease ·Linda Henry, Katherine Eberly, (unknown), Ameeta Ravi Kumar, Zobair M. Younossi	9
5	Economic Burden and Patient-Reported Outcomes of Nonalcoholic Fatty Liver Disease 2023 ·Clinics in Liver Disease ·Maria Stepanova, Linda Henry, Zobair M. Younossi	24
6	Treatment rates and factors associated with direct‐acting antiviral therapy for insured patients with hepatitis C‐related hepatocellular carcinoma – A real‐world nationwide study 2023 ·Alimentary Pharmacology & Therapeutics ·Leslie Y. Kam, Yee Hui Yeo, Fanpu Ji, Linda Henry, Ramsey Cheung, Mindie H. Nguyen	4
7	Increasing number and shifting demographics of adolescent opioid use disorder presentations to the emergency department 2023 ·The American Journal of Emergency Medicine ·(unknown), John M. Howell, Linda Henry, (unknown)	2
8	Non-alcoholic fatty liver disease is associated with greater risk of 30-day hospital readmission in the United States (U.S.) 2023 ·Annals of Hepatology ·James M. Paik, Katherine Eberly, Khaled W. Kabbara, (unknown), Youssef Younossi, Linda Henry, Manisha Verma, Zobair M. Younossi	4
9	The combination of the enhanced liver fibrosis and FIB‐4 scores to determine significant fibrosis in patients with nonalcoholic fatty liver disease 2023 ·Alimentary Pharmacology & Therapeutics ·Zobair M. Younossi, Maria Stepanova, Sean Felix, Thomas L. Jeffers, Elena Younossi, Zachary Goodman, Andrei Racila, Brian Lam, Linda Henry	3
10	Nonalcoholic Fatty Liver Disease Is Independently Associated With Higher All-Cause and Cause-Specific Mortality 2023 ·Clinical Gastroenterology and Hepatology ·Leyla de Avila, Linda Henry, James M. Paik, Naila Ijaz, Ali A. Weinstein, Zobair M. Younossi	14
11	How long is too long: A retrospective study evaluating the impact of the duration of noninvasive oxygenation support strategies (high flow nasal cannula & BiPAP) on mortality in invasive mechanically ventilated patients with COVID-19 2023 ·PLoS ONE ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Brian Lam, Maria Stepanova, Linda Henry, Christopher S. King, Mehul Desai	2
12	The changing epidemiology of adult liver transplantation in the United States in 2013-2022: The dominance of metabolic dysfunction–associated steatotic liver disease and alcohol-associated liver disease breakdown → 2023 ·Hepatology Communications ·Zobair M. Younossi, Maria Stepanova, Reem Q. Al Shabeeb, Katherine Eberly, (unknown), Veronica Nguyen, Janus P. Ong, Linda Henry, Saleh A. Alqahtani	71
13	Outcomes of hospitalized patients with COVID-19 during the course of the pandemic in a fully integrated health system 2022 ·PLoS ONE ·Brian Lam, Maria Stepanova, Chapy Venkatesan, (unknown), (unknown), (unknown), (unknown), Mehul J. Desai, Andrei Racila, (unknown), Linda Henry, Lynn H. Gerber, Zobair M. Younossi	5
14	Nonalcoholic Fatty Liver Disease Prevalence Trends Among Adolescents and Young Adults in the United States, 2007‐2016 2021 ·Hepatology Communications ·Tamoore Arshad, James M. Paik, Rakesh Biswas, Saleh A. Alqahtani, Linda Henry, Zobair M. Younossi	56
15	The comprehensive outcomes of hepatitis C virus infection: A multi‐faceted chronic disease 2018 ·Journal of Viral Hepatitis ·Zobair M. Younossi, George Papatheodoridis, P. Cacoub, Francesco Negro, Heiner Wedemeyer, Linda Henry, Angelos Hatzakis	24
16	Sofosbuvir and ledipasvir are associated with high sustained virologic response and improvement of health‐related quality of life in East Asian patients with hepatitis C virus infection 2018 ·Journal of Viral Hepatitis ·Zobair M. Younossi, Maria Stepanova, Linda Henry, Kwang‐Hyub Han, Sang Hoon Ahn, Young‐Suk Lim, Wan‐Long Chuang, Jia‐Horng Kao, Kinh Van Nguyen, Ching‐Lung Lai, Henry Lik‐Yuen Chan, Lai Wei	14
17	Hepatitis C in Patients With Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes 2017 ·Clinical Infectious Diseases ·Zobair M. Younossi, Maria Stepanova, Tarik Asselah, Graham R. Foster, Keyur Patel, Norbert Bräu, Mark G. Swain, Tram T. Tran, Rafael Esteban, M. Colombo, Stephen Pianko, Linda Henry, Marc Bourlière	18
18	In an era of highly effective treatment, hepatitis C screening of the United States general population should be considered 2017 ·Liver International ·Zobair M. Younossi, (unknown), (unknown), Linda Henry, Youssef Younossi, Rachel Beckerman, Sharon Hunt	31
19	Association of work productivity with clinical and patient‐reported factors in patients infected with hepatitis C virus 2016 ·Journal of Viral Hepatitis ·Zobair M. Younossi, Maria Stepanova, Linda Henry, Issah Younossi, Ali A. Weinstein, Fatema Nader, Sharon Hunt	30
20	Tobacco use triggers for mothers of infants: implications for pediatric nursing practice. 2008 ·PubMed ·Kathleen F. Gaffney, Linda Henry, Charlene Douglas, (unknown)	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact